EFPIA-EURORDIS joint statement published on patientaccess to medicines for rare diseases

The statement contains a series of proposals to improve the lives of people living with rare diseases by addressing access barriers to transformative medicines

The EFPIA-EURORDIS joint statement on patient access to medicines for rare diseases across Europe has been published.

The statement is based on an 18-month structured dialogue between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EURORDIS, a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

Bron: Eurocordis / Efpia